6533b82dfe1ef96bd1290938
RESEARCH PRODUCT
Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study)
Eugenia Di MecoGiuliano RizzardiniFrancesca BaiAntonio CascioAnna Maria CattelanFederica TordatoEvelyn Van HauwermeirenMassimo PuotiChiara AldieriMaria Cristina MoioliFrancesco CastelliGiulia MarchettiGuglielmo MigliorinoPaola MorelliBarbara MenzaghiFederica BorghiMarco RizziAntonella D'arminio MonforteAnnalisa SaracinoFrancesca Raumersubject
0301 basic medicineMicrobiology (medical)Malemedicine.medical_specialtyGram-positive infection030106 microbiologyReal life settingMicrobiology03 medical and health sciences0302 clinical medicineVirologyInternal medicineAntibiotic therapymedicineantibiotic therapyHumansacute bacterial skin and skin structure infection030212 general & internal medicineAgedRetrospective Studiesbusiness.industryDalbavancinOff-Label UseSkin Diseases BacterialMiddle Agedacute bacterial skin and skin structure infectionsAnti-Bacterial Agentssecond-generation lipoglycopeptide antibioticsHospitalizationacute bacterial skin and skin structure infections; antibiotic therapy; dalbavancin; Gram-positive infections; second-generation lipoglycopeptide antibioticsInfectious DiseasesItalyAcute DiseaseSkin structureObservational studyFemalesecond-generation lipoglycopeptide antibiotics.TeicoplaninbusinessGram-positive infectionsdalbavancindescription
Objectives: We evaluated the efficacy and safety of dalbavancin in ABSSSI and ‘other sites’ infections’ (OTA). Methods: Observational study involving 11 Italian hospitals including patients that received ≥1 dose of dalbavancin in 2016–2019. The outcome was end-of-treatment efficacy and safety in ABSSSI and OTA in a real-life setting. Results: 206 patients enrolled (males 50%, median age 62 [IQR 50–76] years), 60.2% ABSSSI, 39.8% OTA. 69.7% ABSSSI vs 90.7% OTA (p = 0.003) and 46.3% ABSSSI vs 37.2% OTA (p = 0.786) received previous and concomitant antibiotics, respectively. 82.5% reached clinical cure. Eleven (5.4%) patients had non-serious adverse events (AE). OTA patients showed longer hospitalization (13.5 days, 5.5–22 vs 3, 0–11.7; p<0.0001) and received longer previous (18 days, 9–30 vs 11, 7–19; p = 0.007)/concomitant antibiotic treatments (21 days, 14–52 vs 11, 8–14; p < 0.0001), compared to ABSSSI. ABSSSI and OTA showed similar efficacy (85.5% vs 75%, p = 0.459) and safety (no AE: 81.5% vs 64.3%, p = 0.258); efficacy was independent of previous/concomitant therapies. Conclusions: Dalbavancin demonstrated a success rate of >80%, with similar efficacy/safety in ABSSSI and off-label indications. The preferential use of dalbavancin as second-line or combination therapy would seem to suggest the need for in-depth studies focused on its off-label use.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2020-01-01 |